Spectrum Health Cardiomyopathy Program named National Center of Excellence

March 29, 2017

GRAND RAPIDS, Mich. - The Spectrum Health Hypertrophic Cardiomyopathy Program has been designated a national Center of Excellence by the Hypertrophic Cardiomyopathy Association (HCMA). Spectrum Health joins 25 other centers nationwide with this recognition, and becomes the second center in the state of Michigan.

Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disorder, and affects at least 1 in 500 people in the United States. It is characterized by abnormal thickening of the heart muscle which can cause multiple problems including obstruction of blood flow out of the heart, congestive heart failure symptoms, or heart rhythm disorders leading to loss of consciousness or sudden cardiac death.

HCMA Centers of Excellence are recognized for providing comprehensive diagnostic, treatment, education and research programs.

"This designation is the culmination of years spent building the necessary resources and collaboration of specialties, followed by an intensive site evaluation of the program by the HCMA," said David Fermin, MD, Spectrum Health Hypertrophic Cardiomyopathy Program medical director. "It provides significant external validation that our multidisciplinary approach, a direct extension of Spectrum's core values, is bringing the best care possible to our patients."

HCM can affect people at nearly any age and often goes undiagnosed. Many people have few, if any, symptoms. Others may experience shortness of breath, dizziness, palpitations or chest discomfort. Some patients experience problems in the heart's electrical system resulting in life-threatening heart rhythms (arrhythmias). Patients diagnosed with HCM require an extensive evaluation, regular follow-up, education, genetic counseling and screening for family members. Some patients may require cardiac surgery to remove the obstructing heart muscle, and/or implantation of a defibrillator to prevent sudden cardiac death.

The Spectrum Health program includes the latest diagnostic techniques, cardiology specialists (trained in advanced imaging, interventional cardiology, heart failure and electrophysiology), a cardiac surgeon, physician assistant, nurse coordinator, genetic counselor and social worker. This facilitates a comprehensive approach to diagnosis, education and treatment.

All HCMA Centers of Excellence are required to provide the following services within their program or through a referral relationship: "Patients with HCM who receive care with HCMA recognized Centers of Excellence programs experience the most time and cost effective care when compared to those seeking care in the general cardiology community," said Lisa Salberg, HCMA Founder and CEO. "Patients and families benefit by receiving comprehensive care by a team of highly skilled clinicians as well as receiving the emotional support they need to balance living with a genetic heart conditions that may well impact many members of the family."

"The Hypertrophic Cardiomyopathy Association is pleased to welcome Spectrum Health to our family of Center of Excellence programs," Salberg said.

"The Spectrum Health Hypertrophic Cardiomyopathy Program is an embodiment of the multidisciplinary collaborative spirit that is central to the culture of Spectrum Health, and one of its greatest strengths," said Penny Wilton, MBBS, Department Chief, Cardiovascular Services, Frederik Meijer Endowed Chair. "Establishing this model of care would not have been possible without the institutional support of the Spectrum Health Frederik Meijer Heart & Vascular Institute."

To learn more about the Spectrum Health Hypertrophic Cardiomyopathy Program, contact the HCM Coordinator at 616.885.5355

Spectrum Health is a not-for-profit health system, based in West Michigan, offering a full continuum of care through the Spectrum Health Hospital Group, which is comprised of 12 hospitals, including Helen DeVos Children's Hospital; about 180 ambulatory and service sites; about 3,200 physicians and advanced practice providers, including about 1,400 members of the Spectrum Health Medical Group; and Priority Health, a health plan with about 791,000 members. Spectrum Health is West Michigan's largest employer, with 25,300 employees. The organization provided more than $326 million in community benefit during its 2016 fiscal year. Spectrum Health was named one of the nation's 15 Top Health Systems--and in the top five among the largest health systems--by Truven Health Analytics™ for 2016. This is the fifth time the organization has received this recognition.

The HCMA, founded in 1996, is a 501(c)(3) organization operating out of Denville, NJ. Over the past 21 years, the HCMA has provided services through their phone-in system to over 5,600 HCM families, representing nearly 40,000 affected, or potentially affected, individuals with HCM. The HCMA has worked to create, support, and enhance over 25 HCMA Recognized HCM Centers of excellence across the United States.

Spectrum Health

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.